Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02522611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 313 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Start date pushed from Aug 27, 2026 to Nov 27, 2026
  2. New version filed on ClinicalTrials.gov
  3. 3 versions Re-verified since Aug 6, 2026, no change to tracked fieldsv309-v311
  4. Start date: Jun 27, 2026 to Aug 27, 2026v308
  5. 2 versions Re-verified since Jun 11, 2026, no change to tracked fieldsv306-v307
Show 42 earlier versionsHide 42 earlier versions
  1. Start date: Apr 27, 2026 to Jun 27, 2026v305
  2. Start date: Feb 27, 2026 to Apr 27, 2026v304
  3. 2 versions Re-verified since Mar 19, 2026, no change to tracked fieldsv302-v303
  4. Start date: Dec 19, 2025 to Feb 27, 2026v301
  5. 2 versions Re-verified since Dec 23, 2025, no change to tracked fieldsv299-v300
  6. Start date: Nov 19, 2025 to Dec 19, 2025v298
  7. Start date: Oct 28, 2025 to Nov 19, 2025v297
  8. Start date: Oct 10, 2025 to Oct 28, 2025v296
  9. Start date: Sep 22, 2025 to Oct 10, 2025v295
  10. Start date: Sep 2, 2025 to Sep 22, 2025v294
  11. 4 versions Re-verified since Jun 28, 2025, no change to tracked fieldsv290-v293
  12. Start date: Jun 2, 2025 to Sep 2, 2025v289
  13. 17 versions Re-verified since Dec 21, 2024, no change to tracked fieldsv272-v288
  14. Start date: Dec 1, 2024 to Jun 2, 2025v271
  15. 6 versions Re-verified since Oct 25, 2024, no change to tracked fieldsv265-v270
  16. Start date: Oct 1, 2024 to Dec 1, 2024v264
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Cancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and quality of life. Researchers believe a research drug called resiniferatoxin (RTX) may be able to help. Objective: To learn whether RTX is safe and can reduce cancer induced bone pain. Eligibility: People ages 18 and older with CIBP that is not relieved by standard treatments Design: Participants will have up to 6 outpatient visits over about 7 months. These will include: Medical history Physical exam Blood and urine tests. Thermal testing: a disk placed on the skin to test ability to sense temperature in and around the area of pain Chest x-ray EKG: stickers are placed on the chest to measure heart signals ECG: measures electrical activity of the heart Participants will have 1 inpatient visit lasting 2-4 days. This will include: Catheter inserted into a vein in the arm. They are given anesthesia, sedation, and x-ray contrast. A needle is passed through the skin of the back to inject the RTX. Participants will keep a log of the pain medications they take after surgery. Participants will be called 1 week and 2, 3, and 4 months after the injection. Participants will be mailed surveys and questionnaires to complete 2, 3, and 4 months after the injection.
Trial Details
NCT Number NCT02522611
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Intractable Pain, Palliative Care
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov